The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
Official Title: NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
Study ID: NCT04302025
Brief Summary: This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope Comprehensive Cancer Center, Duarte, California, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
USC Norris Cancer Center, Los Angeles, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
UCLA Hematology Oncology, Los Angeles, California, United States
The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange, California, United States
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
UCSF, San Francisco, California, United States
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Yale Cancer Center, New Haven, Connecticut, United States
MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington, District of Columbia, United States
Sylvester Comprehensive Cancer Center - Deerfield Beach, Miami, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Northwestern University; Robert H. Lurie Comp Can Ctr, Chicago, Illinois, United States
Dana-Farber Cancer Institute; Brigham and Women's Cancer Center, Boston, Massachusetts, United States
Boston Medical Center, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
University of Missouri Health Care; Ellis Fischel Cancer Center, Columbia, Missouri, United States
HCA Midwest Health, Kansas City, Missouri, United States
Washington University School of Medicine; Sitemann Cancer Center, Saint Louis, Missouri, United States
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York, United States
Columbia University Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Ohio State University; Hemat/Onc, Columbus, Ohio, United States
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
Baptist Clinical Research Institute, Memphis, Tennessee, United States
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
Baylor College of Medicine, Houston, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
Lumi Research, Kingwood, Texas, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR